List view / Grid view

Articles

Advanced techniques and applications of LC-MS in small molecule drug discovery

16 June 2016 | By , , ,

A key process in drug discovery is the ability to identify new drug candidates by screening chemical libraries of small molecules, natural products or extracts against a biological target and selecting lead compounds with desirable therapeutic effects. Medicinal chemistry has the challenging role of not only ensuring that the chemical…

Rare Diseases Q&A

16 June 2016 | By

Releasing colourful balloons into the air to symbolise people who are affected by rare diseases was one of the many ways in which this year’s Rare Disease Day was marked in February. The once-yearly, global campaign aims to raise awareness among the general public and decision-makers about these illnesses and…

Inhibition of RNA-containing viruses by artificial RNases

16 June 2016 | By , , , ,

The toxicity and antiviral properties of 24 low-molecular-weight artificial RNases (artRNases) including peptides, peptidomimetics, N-alkyl-substituted 1,4-diazabicyclo[2.2.2]octane (DABCO) and a silver (I) complex with cystine were analysed for viruses containing single-stranded and double-stranded genomic RNA (the tick-borne encephalitis virus; TBEV and the influenza virus, respectively) in vitro and in vivo by…

Pharmacometabolomics as the key to personalised medicine

12 June 2016 | By ,

Blanketed administration of drugs to all populations assumes that all patients respond similarly. Despite pharmaceutical companies’ efforts to develop drugs with large therapeutic windows, there are often and inevitably subpopulations of individuals who will either not respond to therapy or will respond with adverse effects...

Leaving EU could be a setback for Life Sciences in the UK

8 June 2016 | By Dr Alexander Moscho, Bayer UK & Ireland CEO

In this opinion piece, Dr Alexander Moscho, Bayer UK & Ireland CEO, says a vote to leave the EU will deter investment and make it harder for patients to access new medicines...

PIM/FLT3 dual inhibition

13 May 2016 | By Wojciech Czardybon, PhD, Project Manager, Discovery Laboratory Manager, Selvita S.A.

In this article, Wojciech Czardybon of Selvita discusses the potential of PIM/FLT3 dual inhibition in treating acute myeloid leukaemia and other cancers...

Soligenix on IDR technology and SGX942

10 May 2016 | By Victoria White, Digital Content Producer

We discuss Innate Defense Regulator (IDR) technology with Soligenix's Chief Scientific Officer, Dr Oreola Donini, and find out more about SGX942...

Advancing FLIP inhibitors for the treatment of NSCLC

26 April 2016 | By Victoria White, Drug Target Review

In an exclusive interview, Trevor Perrior, Research Director at Domainex, discusses the cell death regulatory protein FLIP and the potential of FLIP inhibitors as a treatment for NSCLC...

The threat of antibiotic resistance

25 April 2016 | By Victoria White, Drug Target Review

We've created an infographic on the threat of antibiotic resistance, highlighting some of the recommendations made by the Review on Antimicrobial Resistance to date...